Tag Archives | targeted therapy

Risk Off On Biotech Trades-BIIB, GILD, XBI…Update-2

Update 3/25 Mid-Day Trading NAZ Off 1.55% at 4917 “Bubble Talk” Picking Up-Mid Caps Vulnerable Biotech sector selling picked up today with a dramatic shift in sentiment exacerbated by an overall weak market. Also durable goods fell unexpectedly 1.4% in February indicating weak global growth.Technology was the weakest sector down 1.74% but the resilient healthcare […]

Continue Reading 0

Biotech Bull Market-Trends to Watch #2: ETF Review-FBT XBI

Biotech and Healthcare ETFs Hit An All Time High–Another Rally Coming Today 3/20 M&A: Recent buy-outs of Cubist (CBST) for $9.5B and Pharmacyclics (PCYC) for $21B have raised the valuation bar. The healthcare sector remains strong and biopharmaceuticals are key to sales growth. Breakthroughs in genomics, targeted oncology and HCV drugs are blockbuster growth areas. […]

Continue Reading 0

Rayno Life Science Portfolios: AMGN,CLVS,ILMN,RGEN,TMO…Update 3/18

March 18-Stealth Rally With A Tempered Tape In Biotech NASDAQ up 0.92% Biotech stocks lagged the surprising FED rally today maybe because money was moving to other sectors.This bears close watching because only this week biotech stocks hit a new high.Money may be moving to lagging sectors like energy up 2.92% today. Nonetheless healthcare remained […]

Continue Reading 0

What Sell-Off? Biotechs Cruise: CLVS, SGEN

Stocks in Sharp Sell-Off on Potential FED Rate Increase and Strong Dollar Deflation is Still Lurking S&P Down 1.7%, NASDAQ down 1.67% Biotech stocks avoided the severe sell-off today apparently immune to the strong dollar, flat earnings growth and FED interest rate concerns. Although life science stocks were mixed the bellwether ETFs held their ground: […]

Continue Reading

Biotechs Roaring Back: Do They Sense A Deal? Update -1 ABBV/PCYC

Whoa! $261.25 And the winner is Abbvie (ABBV) for $21B! Pharmacyclics Buzz Is Back¬† Biotech stocks covered the green screen today, despite a listless general market, driven by deal talk regarding Pharmacyclics (PCYC). Q4 2014 sales of their potential blockbuster drug Imbruvica for chronic lymphocytic leukemia hit $185M and is forecasted to hit the $1B […]

Continue Reading